This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
How to Find Top-Ranked Stocks to Buy in March
by Benjamin Rains
Exploring how investors can use the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy in March and throughout what looks set to be a strong 2024.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity
by Zacks Equity Research
Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care
by Zacks Equity Research
GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down
by Zacks Equity Research
Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.
Best Growth Stocks to Buy for February 27th
by Zacks Equity Research
POWL, CAH and TXT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2023.
Momentum Monday: Bull Market Continues
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Mondays
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Bruker's (BRKR) New Launches Drive Growth Amid FX Woes
by Zacks Equity Research
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
Philips' (PHG) New Innovation to Boost Radiation-Free Imaging
by Zacks Equity Research
Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.
Here's Why Investors Should Hold Labcorp (LH) Stock for Now
by Zacks Equity Research
Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).
Charles River (CRL) Forges Collaboration With Wheeler Bio
by Zacks Equity Research
Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
by Zacks Equity Research
BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.
Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls
by Zacks Equity Research
Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.
Best Growth Stocks to Buy for February 23rd
by Zacks Equity Research
CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.
Best Value Stocks to Buy for February 23rd
by Zacks Equity Research
BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.